Lantern Pharma
LTRN
21 hedge funds and large institutions have $5.14M invested in Lantern Pharma in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
2,800% more call options, than puts
Call options by funds: $58K | Put options by funds: $2K
0.16% more ownership
Funds ownership: 9.82% → 9.98% (+0.16%)
5% less capital invested
Capital invested by funds: $5.4M → $5.14M (-$260K)
9% less funds holding
Funds holding: 23 → 21 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HKAM
Horizon Kinetics Asset Management
New York
|
+$158K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$106K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$63.9K |
| 4 |
Renaissance Technologies
New York
|
+$18.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$91.4K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$73K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$68.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$43.8K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$6.22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$1.75K | -289 | Closed |
|
27
Bank of America
Charlotte,
North Carolina
| – | -$48 | -8 | Closed |
|
LTRN Hedge Fund Activity: Q1 2023 in Review
21 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2023, worth a combined $5.14M — down 4.8% from $5.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LTRN and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Horizon Kinetics Asset Management, opening a new position worth an estimated $158K. The largest seller was Jane Street, exiting entirely with an estimated $91.4K sold.
- 21 institutional investors held Lantern Pharma (LTRN) as of Q1 2023, down from 23 in Q4 2022.
- Funds reported $5.14M of Lantern Pharma stock for Q1 2023, down 4.8% quarter-over-quarter.
- 4 funds opened new Lantern Pharma positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest Lantern Pharma buyer in Q1 2023 was Horizon Kinetics Asset Management, an estimated $158K added.
- The largest Lantern Pharma seller in Q1 2023 was Jane Street, an estimated $91.4K sold.
Based on aggregated 13F filings for Q1 2023.